Every 8-K that West Pharm Svcs (WST) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow WST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WST filings page.
West Pharmaceutical Services reported strong second-quarter 2026 results, with net sales of $872.3 million, up 13.8%, and organic growth of 12.7%. Diluted EPS was $2.15, up 18.1%, while adjusted-diluted EPS rose 28.8% to $2.37 as gross margin expanded to 37.7% and adjusted operating margin to 22.6%.
Growth was led by the Proprietary Products segment, where net sales increased 16.6% to $722.6 million. High-Value Product Components generated $424.1 million, 49% of total sales, and HVP Delivery Devices $131.2 million, supported by strong Biologics and GLP-1 demand. West Vantage net sales were $149.7 million, up 2.0%, though margins were pressured by a cybersecurity incident.
For the first half of 2026, operating cash flow was $213.9 million, capital expenditures $85.9 million, and free cash flow $128.0 million. The company repurchased 1.8 million shares for $454.3 million and declared a quarterly dividend of $0.22 per share. Full-year 2026 guidance was raised to net sales of $3.345–$3.380 billion and adjusted-diluted EPS of $8.85–$9.05, with Q3 2026 net sales expected at $820–$835 million and adjusted-diluted EPS of $2.14–$2.24.
West Pharmaceutical Services, Inc. entered into an Amended and Restated Technology Exchange and Crosslicense Agreement and two Distributorship Agreements with Daikyo Seiko, Ltd., effective July 14, 2026. The company holds a 49% ownership interest in Daikyo.
The Crosslicense Agreement provides mutual sharing of know-how and cooperation in developing closures, vials, cartridges, syringes and related pharmaceutical packaging and delivery components. Each party may license the other’s know-how, patents and trademarks; Daikyo’s license from West is non-exclusive, while West’s license from Daikyo is exclusive outside Japan, in each case subject to limited exceptions. The arrangement is royalty-free except for a fixed royalty rate on certain patents and non-patented technical information. One Distributorship Agreement grants West exclusive rights to distribute Daikyo products outside Japan, and the other grants Daikyo non-exclusive rights to distribute West products in Japan. Each agreement has a 10-year term and may be terminated earlier under specified circumstances, including mutual consent or a change in control.
West Pharmaceutical Services announced that Michel Lagarde will become President and Chief Executive Officer and join the Board, effective August 31, 2026, succeeding Eric M. Green, who will retire from his roles on that date. Lead Independent Director Robert F. Friel will become Chair of the Board.
Lagarde’s employment agreement sets an annual base salary of $1,175,000 and a target annual incentive equal to 125% of salary, prorated for 2026. He will receive 2026 long‑term incentive awards valued at $8,611,111 and one‑time inducement equity grants with a maximum aggregate value of $10,000,000, combining performance share units, restricted stock units and stock options.
The agreement provides severance protections, including salary continuation and benefits for certain terminations, and enhanced cash and equity vesting if termination occurs within two years after a change in control. Lagarde will relocate to the company’s Exton, Pennsylvania headquarters and continue West’s focus on injectable drug delivery solutions.
West Pharmaceutical Services, Inc. filed an amended report updating details on a previously disclosed material cybersecurity attack. The company states that core enterprise systems are restored and that manufacturing, receiving and shipping processes have restarted at all sites, with global operations now fully functional.
The intrusion was initially detected on May 4, 2026, with data exfiltration and system encryption confirmed by May 7, 2026. The company reports no unauthorized activity or access has been observed since May 5, 2026. Based on its investigation to date, it believes the incident has not had, and is not reasonably likely to have, a material impact on its 2026 second-quarter and full-year financial guidance.
West Pharmaceutical Services, Inc. reported a material cybersecurity attack that involved data being exfiltrated by an unauthorized party and encryption of certain systems. After detecting the intrusion on May 4, 2026, the company took systems offline globally, notified law enforcement, and engaged external cyber‑forensic experts, including Palo Alto Networks’ Unit 42.
The attack and the company’s containment measures have temporarily disrupted business operations worldwide. Core enterprise systems have been restored and key shipping, receiving, and manufacturing processes have restarted at some sites, with other locations still being brought back online. The company has not yet determined the incident’s material impact on its financial condition or results.
West Pharmaceutical Services, Inc. reported results of its 2026 annual shareholder meeting held virtually on May 4, 2026. Shareholders elected eleven directors to serve until the 2027 meeting and approved, on a non-binding basis, compensation for named executive officers.
As of the February 27, 2026 record date, there were 72,081,610 common shares outstanding, and 66,193,322 shares, or 91.83%, were represented at the meeting. Shareholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the 2026 fiscal year and voted against a shareholder proposal seeking an Independent Board Chair Policy.
West Pharmaceutical Services reported a strong first quarter of 2026 and raised its full-year outlook. Net sales reached $844.9 million, up 21.0% from a year earlier, with organic growth of 15.3%. Diluted EPS rose to $1.92, a 56.1% increase, and adjusted-diluted EPS climbed 46.9% to $2.13 as margins improved.
Growth was driven by the Proprietary Products segment, particularly High-Value Product components and delivery devices, and by demand tied to GLP‑1 obesity and diabetes treatments. Management now guides 2026 net sales to $3.295–$3.350 billion and adjusted-diluted EPS to $8.40–$8.75, both above previous ranges. During the quarter, the company generated free cash flow of $47.2 million and repurchased 1.2 million shares for $297.6 million.
West Pharmaceutical Services, Inc. announced that Eric M. Green, its President, Chief Executive Officer and Chair of the Board, plans to retire from all three roles once a successor is hired to support a smooth leadership transition.
The Board has engaged a leading executive recruiting firm and expects the transition to occur in the second half of 2026. At the same time, the Company reaffirmed its previously issued 2026 financial guidance from its February 12, 2026 earnings release.
Green has led West as President and CEO since April 2015 and became Chair in May 2022. During his tenure, the Company more than doubled sales, achieved total shareholder return of approximately 350%, and generated $3.07 billion in net sales in fiscal 2025.
West Pharmaceutical Services, Inc. reported steady growth for the fourth quarter and full year 2025 and issued 2026 guidance. Fourth-quarter net sales were $805.0 million, up 7.5% with 3.3% organic growth, and adjusted diluted EPS rose 12.1% to $2.04.
For 2025, net sales reached $3.074 billion, increasing 6.3% with 4.3% organic growth, while adjusted diluted EPS grew 8.0% to $7.29. Operating cash flow was $754.8 million and free cash flow rose 69.6% to $468.9 million, reflecting lower capital spending.
Management expects 2026 net sales between $3.215 billion and $3.275 billion, implying 5% to 7% organic growth, and adjusted diluted EPS between $7.85 and $8.20, or 7.7% to 12.5% growth. Guidance assumes a mid-2026 close for the SmartDose 3.5mL sale to AbbVie.
West Pharmaceutical Services, Inc. furnished an 8-K announcing its third-quarter 2025 financial results. The company provided a press release and an investor presentation as exhibits.
The materials were furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD). The company noted these items are furnished, not filed, and therefore are not subject to Section 18 liabilities. The press release (Exhibit 99.1) and presentation (Exhibit 99.2) are dated October 23, 2025.
West Pharmaceutical Services reported a leadership change in its legal organization. Kimberly Banks MacKay, Senior Vice President, General Counsel, and Corporate Secretary, will be leaving the company following a transition period. The company and Ms. MacKay plan to determine an appropriate transition that will end no later than December 31, 2025, to support a smooth handover of responsibilities. Until her departure, she will continue in her current role overseeing legal and corporate secretary duties. The company publicly thanked her for her service and contributions and expressed well wishes for her future endeavors.
On 24 July 2025, West Pharmaceutical Services, Inc. (NYSE: WST) filed a Form 8-K disclosing that it has furnished (not filed) its second-quarter 2025 results under Item 2.02 and Item 7.01. The company attached two exhibits:
- 99.1 – press release announcing Q2 2025 financial results
- 99.2 – investor presentation used on the accompanying conference call